1000 WINTER ST, SUITE 1200, WALTHAM, MA
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma Completes $200 Million Convertible Notes Offering
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Zenas BioPharma Approves Amended Short-Term Incentive Plan
Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q2
Q1
FY 2025
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Prospectus filed pursuant to Rule 424(b)(7)